Kinaxis to Unveil the Next Phase of AI Innovation at Kinexions 2025
New agentic and generative AI capabilities will lower the barriers to entry and deliver critical business insights faster
OTTAWA, Ontario, March 11, 2025--(BUSINESS WIRE)--Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, is set to unveil new artificial intelligence capabilities in its Maestro™ platform at Kinexions North America 2025, the company's global innovation conference. These AI capabilities are designed to accelerate the value that AI can create in supply chains, helping companies navigate an increasingly volatile global trade environment - whether they are just beginning their AI journey or already leveraging advanced automation.
The company will introduce AI agents that users can interact with to monitor, predict, and take action in real time — automating key tasks like inventory management and disruption mitigation. In addition, its agentic AI framework will enable companies to easily create their own AI agents on Maestro, making AI-driven supply chain orchestration accessible to businesses at any stage of AI maturity.
Additionally, new generative AI functionality will make interacting with supply chain data even more intuitive: in addition to creating customizable dashboards, users will be able to query their digital twin by asking questions in dozens of natural languages and receive instant, insightful answers to complex questions. This removes the technical skills typically required to interact with data, allowing teams to analyze scenarios, assess risks, and make informed decisions without requiring AI expertise. Existing generative AI from Kinaxis – Maestro Chat – has already been adopted by two-thirds of its user base and this new functionality will build on that success.
Finally, Kinaxis will showcase how it's making predictive AI capabilities even more powerful and easy to use. AI-powered forecasting has traditionally been out of reach for many companies, requiring massive data sets, specialized expertise, and costly infrastructure. The company will build upon its unique machine learning-based sensing and forecasting capabilities that work with a wider range of data sets and that don't require deep AI expertise, so companies of all sizes can take advantage of predictive intelligence.
"AI is transforming supply chains at a faster rate than any other technology has ever done before," said Andrew Bell, chief product officer at Kinaxis. "By democratizing access to critical supply chain intelligence, removing complexity, and enabling increasingly autonomous operations, we are empowering organizations of all sizes and stages of maturity to unlock the real value of AI in their supply chains today."
Kinaxis customers and industry leaders attending Kinexions 2025 will be the first to experience these AI innovations through exclusive demonstrations and hands-on sessions.
"Kinexions is the supply chain innovation event of the year and we're so excited to showcase the latest supply chain AI capabilities there in 2025," continued Bell. "We're staying ahead of what our customers need to remain competitive today and in the future."
For more information on how Kinaxis is shaping the future of AI-driven supply chain orchestration, visit www.kinaxis.com.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today's volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Cautionary Note and Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements are intended to assist readers in understanding management's expectations as the date of this announcement and may not be suitable for other purposes. Forward-looking statements relate to future events and reflect management's expectations or beliefs regarding such future events. In certain cases, statements that contain forward-looking information can be identified by the use of words such as "enable", "increase" "unveil", "will", "make", "allow", "build", "plan", "deliver", "anticipate", "believe" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur" or "be achieved" or the negative of these words or comparable terminology. Forward looking information in this announcement includes statements with respect to Kinaxis' plans and development around AI innovations, and the utility of such innovations for Kinaxis' clients. By its very nature forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual plans, performances or results to be materially different from any anticipated plan, performance or result expressed or implied by such forward-looking statements. We describe many of the risks and uncertainties we face in detail in our 2024 Annual Information Form under the heading Risk Factors, which you can find on SEDAR+ (www.sedarplus.ca). In light of these risks and uncertainties, readers should not place undue reliance on forward-looking statements.
The forward-looking statements made in this announcement relate only to events or information as of the date hereof and are expressly qualified in their entirety by this cautionary statement. Kinaxis does not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future or unanticipated events or otherwise, unless we are required by law to do so.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311610609/en/
Contacts
Media Relations Belinda Thomas | Kinaxisbthomas@kinaxis.com +1 613 322 9305
Investor Relations Rick Wadsworth | Kinaxisrwadsworth@kinaxis.com+1 613-907-7613
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
ICE Mortgage Monitor: Record Levels of Home Equity and Falling Rates Drive Highest HELOC Withdraws Since 2008
48M homeowners sit on $11.5T in tappable equity entering Q2 2025 as HELOC rates ease, driving demand ATLANTA & NEW YORK, June 02, 2025--(BUSINESS WIRE)--ICE Mortgage Technology, a neutral provider of a robust end-to-end mortgage platform and part of Intercontinental Exchange, Inc. (NYSE: ICE), today released its June 2025 Mortgage Monitor report. The analysis of mortgage, real estate and public records data shows U.S. mortgage holders carried a record $17.6 trillion in home equity entering the second quarter of 2025, with $11.5 trillion considered "tappable" — that is, available for borrowing while maintaining at least a 20% equity cushion. Despite subdued withdrawal rates in recent years, early 2025 data points to shifting borrower behavior. First-quarter second lien equity withdrawals rose 22% year over year to nearly $25 billion — the largest first quarter volume in 17 years — suggesting increased interest in home equity access amid improving loan affordability. "Equity levels remain historically high, and now we're seeing the cost of borrowing against that equity drop meaningfully," said Andy Walden, Head of Mortgage and Housing Market Research at ICE. "The monthly payment needed to withdraw $50,000 via a home equity line of credit (HELOC) has fallen by more than $100 since early 2024. If the Fed moves forward with anticipated rate cuts, borrowing against home equity could become even more attractive in the second half of the year." The average introductory rate on second lien HELOCs has declined by 2.5 percentage points in recent quarters, dropping below 7.5% in March. If current market forecasts hold, HELOC rates could dip into the mid-6% range by 2026 — roughly on par with projected 30-year mortgage rates. This easing has already translated into lower monthly payments for borrowers. According to ICE's McDash Home Equity database, the average monthly payment needed to borrow $50,000 dropped from $412 in early 2024 to $311 by the end of the first quarter of 2025. Other highlights from the June 2025 Mortgage Monitor include: 48 million mortgage holders have tappable equity, with the average homeowner sitting on $212K. Mortgaged homes are, on average, only 45% leveraged, suggesting ample cushion for equity access. Lenders are becoming more aggressive with their HELOC rate offerings, with the spread to prime falling to the lowest levels since 2022. Equity withdrawals — including cash-out refinances — totaled $45 billion in the first quarter of 2025, the highest first quarter volume since 2022. Borrowers tapped just 0.41% of available tappable equity in the first quarter of 2025, still below long-term averages, indicating further room for growth. "In our latest ICE Borrower Insights Survey, roughly 25% of homeowners said they are considering a home equity loan or HELOC in the next year. It's periods like these — where both demand and affordability trends converge — that represent a critical opportunity for housing finance professionals to earn homeowners' repeat business," said Tim Bowler, President of ICE Mortgage Technology. "As a neutral technology provider dedicated to the success of our lender and servicer clients, we've invested heavily in developing an advanced, end-to-end mortgage platform that engages borrowers with timely, relevant offers while keeping costs in check. It's one of the ways we're helping our clients remain responsive, serve their communities and retain customers in a changing market." The full June Mortgage Monitor report also contains a deep analysis of April mortgage performance data and a housing market update featuring May ICE Home Price Index (HPI) data. Further detail, including charts, can be found in this month's Mortgage Monitor. About the ICE Mortgage Monitor ICE manages the nation's leading repository of loan-level residential mortgage data and performance information covering the majority of the overall market, including tens of millions of loans across the spectrum of credit products and more than 160 million historical records. The ICE Home Price Index provides one of the most complete, accurate and timely measures of home prices available, covering 95% of U.S. residential properties down to the ZIP code level. In addition, the company maintains one of the most robust public property records databases available, covering 99.9% of the U.S. population and households from more than 3,100 counties. ICE's research experts carefully analyze this data to produce a summary supplemented by dozens of charts and graphs that reflect trend and point-in-time observations for the monthly Mortgage Monitor report. To review the full report, visit: About Intercontinental Exchange Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds, and operates digital networks that connect people to opportunity. We provide financial technology and data services across major asset classes helping our customers access mission-critical workflow tools that increase transparency and efficiency. ICE's futures, equity, and options exchanges -- including the New York Stock Exchange -- and clearing houses help people invest, raise capital and manage risk. We offer some of the world's largest markets to trade and clear energy and environmental products. Our fixed income, data services and execution capabilities provide information, analytics and platforms that help our customers streamline processes and capitalize on opportunities. At ICE Mortgage Technology, we are transforming U.S. housing finance, from initial consumer engagement through loan production, closing, registration and the long-term servicing relationship. Together, ICE transforms, streamlines, and automates industries to connect our customers to opportunity. Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading "Key Information Documents (KIDS)." Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 -- Statements in this press release regarding ICE's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE's Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 6, 2025. Source: Intercontinental Exchange Category: Mortgage Technology ICE-CORP View source version on Contacts ICE Media Contact:Johnna +1 (404) 798-1155 ICE Investor Contact:Katia +1 (678) 981-3882 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Innovex Expands Platform With Highly Accretive Acquisition of Citadel Casing Solutions
HOUSTON, June 02, 2025--(BUSINESS WIRE)--Innovex International, Inc. (NYSE: INVX) (the "Company" or "Innovex") is pleased to announce that it has completed the acquisition of Citadel Casing Solutions, LLC ("Citadel"), leveraging its unique, energy industrial platform. This investment meets all the criteria of the Company's disciplined M&A framework, including a focus on single-use, highly engineered products that share the Company's "Big Impact, Small Ticket" value proposition. Founded in 2016 by a team of industry experts, Citadel is a leading provider of differentiated downhole technologies which are designed to improve its customers' economics by driving reduced cycle times through improved operational efficiencies. The acquisition is financially attractive even prior to expected synergies. The transaction values Citadel at approximately 3.8x LTM Adjusted EBITDA1 and is 8% accretive to Innovex's EPS2. Innovex anticipates realizing approximately $2 million of cost synergies within 3 months and anticipates further synergies longer term as the business is fully integrated. "We are excited to add another strong team and complementary set of products to Innovex's portfolio," said Adam Anderson, CEO of Innovex. "Citadel has successfully grown its business through-cycle by adhering to a culture which is in line with our 'No-Barriers' approach. Citadel's products drive efficiencies by reducing cycle times, and its TrenchFoot™ Wet Shoe technology increases reservoir access resulting in increased production for our customers. As a result of its technology centric approach, Citadel has outgrown the market over the last few years, and we expect this to continue over the next few years. This acquisition bolsters our leadership position in the cementing tool market in US Land and supports our efforts to grow market share in the offshore and international markets." "We are excited to accelerate our growth under the Innovex banner by tapping into its broad, complementary product portfolio and geographical exposure," said Todd Stair, CEO of Citadel. "The combination of our teams and technologies will enhance our ability to help operators deliver efficient wells, furthering our like-minded mission to help bring reliable and affordable energy to the world." "The acquisition of Citadel fits perfectly within our M&A framework," said Kendal Reed, CFO of Innovex. "Citadel's portfolio of Big Impact, Small Ticket products has allowed it to achieve rapid, profitable growth while delivering exceptional returns on capital. We were able to acquire Citadel at a favorable multiple and strong acquisition-level returns even before considering revenue and cost synergies. Importantly, the transaction is highly accretive to our earnings and cash flow per share. Given our strong balance sheet and cash flow generative business model, we were able to acquire Citadel in an all-cash transaction while maintaining an extremely conservative leverage profile and an active corporate buyback program. We expect this acquisition to drive ROCE3 well in excess of idle balance sheet cash, improving long-term returns for our shareholders." Advisors Akin Gump Strauss Hauer & Feld LLP served as legal advisor to Innovex. Piper Sandler served as exclusive financial advisor to Citadel, and Troutman Pepper Locke LLP served as Citadel's legal advisor. About Innovex Innovex International, Inc (NYSE: INVX) is a Houston-based company established in 2024 following the merger of Dril-Quip, Inc and Innovex Downhole Solutions. Our comprehensive portfolio extends throughout the lifecycle of the well; and innovative product integration ensures seamless transitions from one well phase to the next, driving efficiency, lowering cost, and reducing the rig site service footprint for the customer. With locations throughout North America, Latin America, Europe, the Middle East and Asia, no matter where you need us, our team is readily available with technical expertise, conventional and innovative technologies, and ever-present customer service. About Citadel Founded in 2016, Citadel was established to revolutionize casing technology through continuous innovation. Citadel's high-quality, reliable downhole tools are used globally, driving efficiency and performance in the Oil and Gas sector. By combining internal R&D with strategic partnerships, Citadel remains at the forefront of technological advancements in casing solutions. Non-GAAP Financial Measures Adjusted EBITDA is a non-GAAP financial measure. Innovex defines Citadel's Adjusted EBITDA as net income before interest expense, income tax expense, depreciation and amortization, deal costs and board retention agreements, net, further adjusted to exclude certain items which Citadel believes are not reflective of its ongoing performance or which are non-cash in nature. Citadel management used Adjusted EBITDA to assess the profitability of its business operations and to compare Citadel's operating performance to its competitors without regard to the impact of financing methods and capital structure and excluding costs that management believes do not reflect its ongoing operating performance. Adjusted EBITDA does not represent and should not be considered as an alternative to, or more meaningful than, net income or any other measure of financial performance presented in accordance with GAAP as measures of Citadel's financial performance. Innovex's computation of Citadel's Adjusted EBITDA may differ from computations of similarly titled measures of other companies. Innovex utilizes Return on Capital Employed ("ROCE") (a non-GAAP measure) to assess the effectiveness of its capital allocation over time and to compare its capital efficiency to its competitors. Innovex defines ROCE as Income from Operations, before acquisition and integration costs and after tax (resulting in Adjusted Income from Operations, after tax) divided by average capital employed. Capital employed is defined as the combined values of debt and stockholders' equity. Forward-Looking Statements Certain statements contained in this press release and oral statements made regarding the matters addressed in this release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of Innovex's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology including "may," "believe," "expect," "intend," "anticipate," "plan," "should," "estimate," "continue," "potential," "will," "hope" or other similar words and include the Company's expectation of future performance contained herein. These statements discuss future expectations or state other "forward-looking" information, including without limitation statements regarding the expected benefits of the acquisition. You are cautioned not to place undue reliance on any forward-looking statements, which can be affected by assumptions used or by risks or uncertainties. Consequently, no forward- looking statements can be guaranteed. These statements reflect management's expectations based on currently available information and involve significant risks, uncertainties and assumptions that may cause actual results to differ materially. Factors that may cause such differences include, but are not limited to, economic conditions and other factors noted in the Company's Annual Report on Form 10-K, any Quarterly Reports on Form 10-Q and the other documents that the Company files with the Securities and Exchange Commission. Innovex disclaims any duty to update and does not intend to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release, except as may be required by law. ________________________________________ 1 Citadel's LTM Adjusted EBITDA as of 04/30/2025. Adjusted EBITDA is a non-GAAP measure. A reconciliation of Citadel's LTM Adjusted EBITDA to Citadel LTM net income, the most directly comparable financial measures presented in accordance with GAAP, is outlined in the reconciliation table accompanying this release. 2 Reflects LTM as-reported net income for both Innovex and Citadel as of 03/31/2025. The net income amount does not give effect to costs, charges, synergies, or other similar items that could result from a combined company. The share count uses Innovex's outstanding share count as of 03/31/2025. As Citadel is a passthrough entity, Citadel did not incur any income tax expenses. As a combined company, income tax expenses would be expected. Therefore, for the purpose of calculating EPS, an assumed tax rate of 21% was used. 3 Return on Capital Employed ("ROCE") is a non-GAAP measure. Innovex International, Inc. Reconciliation of Citadel's Net Income to Adjusted EBITDA (in thousands) (Unaudited) CitadelLTM April 30, 2025 Revenue $ 71,965 Net Income $ 15,098 Interest expense 513 Income tax expense - Depreciation and amortization 2,600 Other expense/income - EBITDA $ 18,212 Deal Costs 185 Board Retention Agreements 64 Adjusted EBITDA $ 18,461 Net Income (Loss) % Revenue 21 % Adjusted EBITDA Margin1 26 % Note: Figures shown above reflect unaudited results. A quality of earnings analysis was conducted to verify the figures shown. (1) Underlying calculation is not rounded. View source version on Contacts Investor Relations Contact Avinash CuddapahSr. Director – Investor Relationsinvestors@ (346) 398-0000
Yahoo
18 minutes ago
- Yahoo
AVRICORE HEALTH CORPORATE UPDATE: Q1 Results and Ongoing Progress Report
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the 'Company' or 'Avricore') reports on its result for the first quarter of 2025 and its progress towards expansion objectives for the balance of the year. For the three months ended March 31, 2025 the Company realized revenues of $434,061 with a gross profit of $346,297. The Company recorded a comprehensive loss of $77,300 with a net increase in cash of $137,068. Plan the Work – Work the Plan The Company is currently executing its plan to significantly expand HealthTab, its wholly owned turnkey point-of-care testing (POCT) platform that empowers pharmacies to become proactive community diagnostic centers, in the United Kingdom — a decision aligned with the region's robust healthcare market and significant investment in pharmacy-led services. To realize its goals, the Company has ensured its cash position is strong and has the assets needed to capitalize on scale up demand. Therefore, while its previously announced scale down of revenues within Canada has taken effect, the Company continues to be very well positioned to realize its objectives. 'Every day, we're proving just how valuable HealthTab™ can be in the hands of pharmacists,' said Hector Bremner, CEO of Avricore Health. 'The NHS is paving the way for expanded pharmacy services, and our work in the London feasibility study gives us real confidence that HealthTab™ will be part of that future.' Tackling the Need Healthcare systems globally are under increasing pressure due to budget constraints, clinician shortages, and rising demand for services. In Canada, over 6 million people lack access to a family doctor, and among those who do, only 29% receive timely care. Compounding the challenge, nearly a third of family doctors are expected to retire or leave the profession within the next three years. In the UK, with just 25% of physicians serving as GPs, individual practitioners are managing caseloads averaging 2,300 patients each. As these strains intensify, pharmacy is emerging as a key player in delivering primary care services. HealthTab™ is at the forefront of this shift—offering pharmacists tools to conduct essential screenings, identify urgent care needs, and forge deeper patient relationships. The platform reduces the burden on traditional healthcare settings and helps drive efficiencies in care delivery. The market demand for point-of-care solutions continues to grow, accelerated by the need for cost-effective, scalable, and decentralized care. HealthTab™ is uniquely positioned to meet this demand, providing innovative solutions where and when patients need them most. Financial Snapshot The following financial data for the three years is derived from the Annual Audited Consolidated Financial Statements and should be read in conjunction with the Consolidated Financial Statements. 2024 2023 2022 Total revenue $ 4,785,711 $ 3,485,147 $ 1,768,374 Loss from operations $ (668,977) $ (701,215) $ (818,228) Loss per share – basic and diluted $ (0.01) $ (0.01) $ (0.01) Total assets $ 2,298,544 $ 2,538,205 $ 2,568,983 Total current liabilities (1) $ 330,817 $ 529,218 $ 604,893 Total non-current financial liabilities Nil Nil Nil (1) 2022 Current liabilities include deferred revenue of $252,000 for which the Company completed delivery in Q1 2023. Quarterly Financial Information The following table highlights selected unaudited consolidated financial data for each of the eight most recent quarters. These results are not necessarily indicative of results for any future period and you should not rely on these results to predict future performance. Quarter Ended March2025 Dec2024 Sep2024 June2024 March2024 Dec2023 Sep2023 June2023 Revenue 434,061 1,421,076 1,195,122 1,045,206 1,124,307 1,354,403 953,454 548,049 Gross profit 346,297 589,930 434,791 370,775 484,791 501,466 261,778 229,471 Share-based compensation 61,861 174,013 338,089 1,598 27,464 142,765 304,328 168,518 Comprehensive income (loss) (77,300) (712,521) (179,065) 54,022 168,537 59,584 (285,062) (284,225) Net profit (loss)/share (0.00) (0.01) (0.00) 0.00 0.00 (0.00) (0.00) (0.00) Total Assets 2,139,345 2,298,544 3,024,103 2,618,384 2,798,058 2,538,205 2,453,136 2,143,810 HealthTab™ Fast Facts Point of Care Testing Market to reach $93.21 Billion USD in 2030 (Source) Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed (Source) Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source) Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. (Source) There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK. About HealthTab™ HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API. About Avricore Health Inc. Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab™, a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies. Contact: Avricore Health Bremner, CEO 604-773-8943info@ Cautionary Note Regarding Forward-Looking Statements Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
